Takara Bio Inc
Takara Bio Inc., together with its subsidiaries, engages in the businesses of reagents, equipment, contract services, and genetic medicine in Japan, China, the rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including reagents needed for genetic and cellular research, PCR instruments, cellular analysis devices, and in vitro diagnostics for… Read more
Takara Bio Inc (TF2) - Total Assets
Latest total assets as of September 2025: €131.85 Billion EUR
Based on the latest financial reports, Takara Bio Inc (TF2) holds total assets worth €131.85 Billion EUR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Takara Bio Inc - Total Assets Trend (2014–2025)
This chart illustrates how Takara Bio Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Takara Bio Inc - Asset Composition Analysis
Current Asset Composition (March 2025)
Takara Bio Inc's total assets of €131.85 Billion consist of 46.0% current assets and 54.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 23.6% |
| Accounts Receivable | €13.26 Billion | 10.6% |
| Inventory | €12.44 Billion | 9.9% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €1.46 Billion | 1.2% |
| Goodwill | €6.52 Billion | 5.2% |
Asset Composition Trend (2014–2025)
This chart illustrates how Takara Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Takara Bio Inc's current assets represent 46.0% of total assets in 2025, a decrease from 66.9% in 2014.
- Cash Position: Cash and equivalents constituted 23.6% of total assets in 2025, up from 10.3% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 2.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 10.6% of total assets.
Takara Bio Inc Competitors by Total Assets
Key competitors of Takara Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Takara Bio Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Takara Bio Inc generates 0.36x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Takara Bio Inc generates $ 0.83 in net profit.
Takara Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.50 | 9.51 | 4.61 |
| Quick Ratio | 3.96 | 7.60 | 3.51 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €35.99 Billion | € 57.06 Billion | € 28.88 Billion |
Takara Bio Inc - Advanced Valuation Insights
This section examines the relationship between Takara Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.90 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 3.4% |
| Total Assets | €125.33 Billion |
| Market Capitalization | $278.76 Million USD |
Valuation Analysis
Below Book Valuation: The market values Takara Bio Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Takara Bio Inc's assets grew by 3.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Takara Bio Inc (2014–2025)
The table below shows the annual total assets of Takara Bio Inc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | €125.33 Billion | +3.37% |
| 2024-03-31 | €121.25 Billion | -6.15% |
| 2023-03-31 | €129.20 Billion | +11.66% |
| 2022-03-31 | €115.71 Billion | +28.93% |
| 2021-03-31 | €89.75 Billion | +19.65% |
| 2020-03-31 | €75.01 Billion | +5.59% |
| 2019-03-31 | €71.04 Billion | +3.17% |
| 2018-03-31 | €68.85 Billion | +2.55% |
| 2017-03-31 | €67.14 Billion | +0.83% |
| 2016-03-31 | €66.59 Billion | +0.25% |
| 2015-03-31 | €66.42 Billion | +6.28% |
| 2014-03-31 | €62.50 Billion | -- |